FDA ends shortage of weight-loss and diabetes drugs Mounjaro and Zepbound

The FDA has declared the shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, is over. This means compounding pharmacies must stop making their versions of these drugs within 90 days. During the shortage, these pharmacies provided compounded alternatives as affordable options. The FDA's ruling ends this practice, which became popular among patients. Eli Lilly, the drugmaker, successfully challenged the FDA's previous shortage declaration. The FDA considers various factors before resolving a drug shortage, including supply and demand.